Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EBITDA: 2017-2025

Historic EBITDA for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.3 million.

  • Cidara Therapeutics' EBITDA fell 421.36% to -$83.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 53.10%. This contributed to the annual value of -$169.8 million for FY2024, which is 640.60% down from last year.
  • As of Q3 2025, Cidara Therapeutics' EBITDA stood at -$83.3 million, which was down 224.05% from -$25.7 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' EBITDA registered a high of $14.2 million during Q3 2022, and its lowest value of -$91.2 million during Q2 2024.
  • For the 3-year period, Cidara Therapeutics' EBITDA averaged around -$29.6 million, with its median value being -$16.0 million (2024).
  • Per our database at Business Quant, Cidara Therapeutics' EBITDA surged by 178.78% in 2022 and then tumbled by 1,527.98% in 2024.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' EBITDA stood at -$16.8 million in 2021, then grew by 19.08% to -$13.6 million in 2022, then skyrocketed by 76.37% to -$3.2 million in 2023, then plummeted by 1,527.98% to -$52.3 million in 2024, then plummeted by 421.36% to -$83.3 million in 2025.
  • Its last three reported values are -$83.3 million in Q3 2025, -$25.7 million for Q2 2025, and -$23.5 million during Q1 2025.